LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives Consensus Rating of "Hold" from Analysts

Key Points

• Analysts maintain a “Hold” consensus on LeMaitre Vascular, with six hold ratings and three buys. The average 12-month price target is $110.60, though several firms recently downgraded their ratings or lowered targets.
• LMAT shares opened at $78.97, near their 52-week low, after declining below both the 50-day and 200-day moving averages. The company’s latest quarterly EPS of $0.74 missed estimates of $0.81, while revenue rose 9.6% year over year to $70.38 million.
• Institutional investors and hedge funds own 84.64% of the stock. LeMaitre also declared a quarterly dividend of $0.25 per share, equivalent to a $1.00 annualized payout and a 1.3% yield.

Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) have received an average rating of "Hold" from the nine research firms that are covering the firm, MarketBeat reports. Six investment analysts have rated the stock with a hold recommendation and three have assigned a buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $110.60.

LMAT has been the topic of several research reports. Weiss Ratings lowered LeMaitre Vascular from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Friday, August 14th. Citizens Jmp lifted their price objective on shares of LeMaitre Vascular from $118.00 to $127.00 and gave the stock a "market outperform" rating in a report on Wednesday, May 6th. Zacks Research lowered shares of LeMaitre Vascular from a "strong-buy" rating to a "hold" rating in a research note on Monday, July 6th. Barrington Research cut shares of LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a report on Wednesday, August 5th. Finally, Wells Fargo & Company reduced their price target on shares of LeMaitre Vascular from $104.00 to $94.00 and set an "equal weight" rating on the stock in a research report on Wednesday, August 5th.

Hedge Funds Weigh In On LeMaitre Vascular

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Sound Income Strategies LLC raised its position in shares of LeMaitre Vascular by 425.6% during the 1st quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier's stock worth $25,000 after purchasing an additional 183 shares during the period. Catalyst Capital Advisors LLC bought a new position in LeMaitre Vascular during the 1st quarter worth $32,000. Geneos Wealth Management Inc. increased its position in LeMaitre Vascular by 250.3% in the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier's stock worth $47,000 after buying an additional 398 shares during the period. EverSource Wealth Advisors LLC bought a new stake in LeMaitre Vascular in the second quarter valued at $47,000. Finally, Quarry LP lifted its stake in LeMaitre Vascular by 267.2% in the third quarter. Quarry LP now owns 727 shares of the medical instruments supplier's stock valued at $64,000 after buying an additional 529 shares during the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

LeMaitre Vascular Stock Down 1.2%

NASDAQ:LMAT opened at $78.97 on Wednesday. The company has a market capitalization of $1.81 billion, a price-to-earnings ratio of 27.71, a price-to-earnings-growth ratio of 2.31 and a beta of 0.53. LeMaitre Vascular has a one year low of $78.29 and a one year high of $118.01. The stock has a 50-day simple moving average of $93.85 and a 200 day simple moving average of $99.56. The company has a debt-to-equity ratio of 0.40, a quick ratio of 13.96 and a current ratio of 16.31.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its quarterly earnings data on Tuesday, August 4th. The medical instruments supplier reported $0.74 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.81 by ($0.07). LeMaitre Vascular had a net margin of 25.02% and a return on equity of 15.63%. The firm had revenue of $70.38 million for the quarter, compared to analyst estimates of $71.47 million. During the same quarter in the previous year, the company earned $0.60 EPS. The company's quarterly revenue was up 9.6% compared to the same quarter last year. Sell-side analysts predict that LeMaitre Vascular will post 2.89 EPS for the current fiscal year.

LeMaitre Vascular Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 3rd. Investors of record on Thursday, August 20th will be paid a dividend of $0.25 per share. The ex-dividend date is Thursday, August 20th. This represents a $1.00 annualized dividend and a yield of 1.3%. LeMaitre Vascular's dividend payout ratio is 35.09%.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company's offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre's product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source